Freshfields Bruckhaus Deringer has advised YiChang HEC ChangJiang Pharmaceutical on its Hong Kong IPO.

The value of the listing, which commenced trading on 29 December 2015, is US$173m.

YiChang HEC ChangJiang Pharmaceutical is a leading manufacturer and distributor of pharmaceutical products in mainland China, with an emphasis on metabolic and endocrine antiviral products.

The Freshfields team advising on the transaction was led by corporate partner Richard Wang and US corporate partner David Ludwick.